ACTAS UROLOGICAS ESPANOLAS, cilt.38, sa.8, ss.515-522, 2014 (SCI-Expanded)
Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.